L. Hemkens, U. Grouven, and R. Bender, Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study, Diabetologia, vol.180, issue.9, pp.1732-1744, 2009.
DOI : 10.1007/s00125-009-1418-4

H. Yki-järvinen, R. Kauppinen-mäkelin, and M. Tikkainen, Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study, Diabetologia, vol.87, issue.3, pp.442-451, 2006.
DOI : 10.1007/s00125-005-0132-0

C. Pan, P. Sinnassamy, K. Chung, and K. Kim, Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients, Diabetes Research and Clinical Practice, vol.76, issue.1, pp.111-118
DOI : 10.1016/j.diabres.2006.08.012

M. Riddle, J. Rosenstock, and J. Gerich, The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients, behalf of the Insuline Glargine 4002 Study Investigators, pp.3080-3086, 2003.
DOI : 10.2337/diacare.26.11.3080

H. Colhoun, . Sdrn-epidemiology, and . Group, Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group, Diabetologia, vol.40, issue.9, pp.1755-17652469, 2009.
DOI : 10.1007/s00125-009-1453-1

R. Bender and S. Lange, Adjusting for multiple testing???when and how?, Journal of Clinical Epidemiology, vol.54, issue.4, pp.343-349, 2001.
DOI : 10.1016/S0895-4356(00)00314-0

U. Smith and E. Gale, Does diabetes therapy influence the risk of cancer?, Diabetologia, vol.51, issue.9, pp.1699-1708, 2009.
DOI : 10.1007/s00125-009-1441-5